CDKN2A variants in a population-based sample of Queensland families with melanoma

Journal of the National Cancer Institute

Volumn 91, Issue 5, 1999, Pages 446-452

  Aitken, Joanne ^a   Welch, John ^a   Duffy, David ^a   Milligan, Amanda ^a   Green, Adele ^a   Martin, Nicholas ^a   Hayward, Nicholas ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; GUANOSINE; PROTEIN P16;

AGAR GEL ELECTROPHORESIS; ARTICLE; AUSTRALIA; CHROMOSOME 12; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; GENE LOCUS; GENE MUTATION; GENETIC SCREENING; HEREDITY; HIGH RISK POPULATION; HUMAN; MELANOMA; MUTATION RATE; PRIORITY JOURNAL;

EID: 0033518889     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.5.446     Document Type: Article

References (45)

1. Walker GJ, Hussussian CJ, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 1995;4:1845-52.
2. Holland EA, Beaton SC, Becker TM, Grulet OM, Peters BA, Rizos H, et al. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 1995;11:.2289-94.
3. Flores JF, Pollock PM, Walker GJ, Glendening JM, Lin AH, Palmer JM, et al. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene 1997;15:2999-3005.
4. Gruis NA, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 1995;5:169-77.
5. Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, et al. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 1997;6:2061-7.
6. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 1998;7:209-16.
7. Ciotti P, Strigini P, Bianchi-Scarra G. Familial melanoma and pancreatic cancer. Ligurian Skin Tumor Study Group [letter]. N Engl J Med 1996; 334:469-70.
8. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
9. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, et al. Analysis of the p16 gene (CDKN2A) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:23-6.
10. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 1994;54:5269-72.
11. INK4 mutations. N Engl J Med 1995;333:970-4.
12. FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, et al. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A 1996;93:8541-5.
13. Borg A, Johannsson U, Johannsson O, Hakansson S, Westerdahl J, Masback A, et al. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 1996;56:2497-500.
14. Platz A, Hansson J, Mansson-Brahme E, Lagerlof B, Linder S, Lundqvist E, et al. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997;89:697-702.
15. INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-9.
16. Pollock PM, Pearson JV, Hayward NK. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer 1996;15:77-88.
17. Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, et al. Mutations associated with familial melanoma impair p16INK4 function [letter]. Nat Genet 1995;10:114-6.
18. Reymond A, Brent R. p16 proteins from melanoma-prone families are deficient in binding to Cdk4. Oncogene 1995;11:1173-8.
19. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995;375: 506-10.
20. Liu L, Lassam NJ, Slingerland JM, Bailey D, Cole D, Jenkins R, et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 1995;11:405-12.
21. INK4a allele. J Natl Cancer Inst 1996;88:1489-91.
22. Sun S, Pollock PM, Liu L, Karimi S, Jothy S, Milner BJ, et al. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer 1997;73:531-6.
23. Aitken JF, Duffy DL, Green A, Youl P, MacLennan R, Martin NG. Heterogeneity of melanoma risk in families of melanoma patients. Am J Epidemiol 1994;140:961-73.
24. Aitken JF, Green AC, MacLennan R, Youl P, Martin NG. The Queensland Familial Melanoma Project: study design and characteristics of participants. Melanoma Res 1996;6:155-65.
25. Aitken JF, Youl P, Green A, MacLennan R, Martin NG. Accuracy of case-reported family history of melanoma in Queensland, Australia. Melanoma Res 1996;6:313-7.
26. Cannings C, Thompson EA. Ascertainment in the sequential sampling of pedigrees. Clin Genet 1977;12:208-12.
27. Aitken JF, Green A, MacLennan R, Jackman L, Martin NG. Comparability of surrogate and self-reported information on melanoma risk factors. Br J Cancer 1993;67:1036-41.
28. Heath AC, Bucholz KK, Madden PA, Dinwiddie SH, Slutske WS, Bierut LJ, et al. Genetic and environmental contributions to alcohol dependence risk in a national twin sample: consistency of findings in women and men. Psychol Med 1997;27:1381-96.
29. Holman CD, Armstrong BK, Heenan PJ, Blackwell JB, Cumming FJ, English DR, et al. The causes of malignant melanoma: results from the West Australian Lions Melanoma Research Project. Recent Results Cancer Res 1986;102:18-37.
30. Ford D, Bliss JM, Swerdlow AJ, Armstrong BK, Franceschi S, Green A, et al. Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995;62:377-81.
31. Bliss JM, Ford D, Swerdlow AJ, Armstrong BK, Cristofolini M, Elwood JM, et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995; 62:367-76.
32. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16: 1215.
33. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
34. Terwilliger JD, Ott J. Handbook of human genetic linkage. Baltimore (MD): The Johns Hopkins University Press; 1994.
35. Weir BS. Genetic data analysis II. Sunderland (U.K.): Sinauer Associates; 1996.
36. Weeks DE, Lange K. The affected-pedigree-member method of linkage analysis. Am J Hum Genet 1988;42:315-26.
37. Lange K, Weeks D, Boenhke M. Programs for pedigree analysis: MENDEL, FISHER and dGENE. Genet Epidemiol 1998;5:471-2.
38. Boehnke M. Allele frequency estimation from data on relatives. Am J Hum Genet 1991;48:22-5.
39. Whiteman DC, Milligan A, Welch J, Green AC, Hayward NK. Germline CDKN2A mutations in childhood melanoma [letter]. J Natl Cancer Inst 1997;89:1460.
40. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998; 338:879-87.
41. Bahuau M, Vidaud D, Jenkins R, Bieche I, Kimmel DW, Assouline B, et al. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 1998;58:2298-303.
42. Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, et al. CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res 1997;57:4868-75.
43. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993;52:506-16.
44. Box NF, Wyeth JR, O'Gorman LE, Martin NG, Sturm RA. Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum Mol Genet 1997;6:1891-7.
45. Valverde P, Healy E, Sikkink S, Haldane F, Thody AJ, Carothers A, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996;5:1663-6.